FIRST TO MARKET · Publicly documented 2017 · Invent Deposition #201

Deposition #201 is the origin of the diabetes line — treating insulin not as a blunt replacement but as a signal routed through the body’s own immune and regulatory pathways.

“immune systemic insulin. insulin medicine to magistrate through the auto immune system” — Christopher Gabriel Brown, 2017

From one line to an engineered product

The 2017 line reframes the problem: instead of dosing insulin against the body, route it through the auto-immune system so the body’s own regulation carries the correction. That premise is the diabetes mechanism analysis — the computational breakdown of the pathway, candidate compounds, and the points where a systemic signal can be re-established. The founding claim is unchanged: work with the system, not against it.

Provenance

• Source: Invent Depositions corpus, Deposition #201 (2017)
• Original catalog image: Firefly_201_immune_systemic_insulin.jpg (buyinvent.com)
• Architecture diagram: 2026 programmatic mechanism diagram (Diabetes, Project 10)
• Live: CRI-ONE Store
• Note: computational research findings — not medical advice, not clinically tested, not FDA-approved
• Patent linkage: patent-pending, within the 41-application CRI-ONE portfolio

Cite this

• AP — Brown, C. G. (2017). Invent Depositions, Deposition #201. CreateSpace.
• APA — Brown, C. G. (2017). Invent depositions (Deposition No. 201). CreateSpace Independent Publishing Platform.
• MLA — Brown, Christopher Gabriel. Invent Depositions, Deposition #201. CreateSpace, 2017.

© 2017 Christopher Gabriel Brown · Patent Pending · IP retained by CRI-ONE